Bethan Chalmers

Cooley advised Hummingbird Bioscience, a Singapore-based biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases, on its exclusive worldwide license agreement with Callio Therapeutics, a newly launched biotech company focused on realizing the promise of multipayload antibody-drug conjugates (ADCs) to improve cancer therapy.

Cooley advised Battery Ventures, a global, technology-focused investment firm, on its strategic, majority growth investment in QSR Automations, a global leader in restaurant technology.

Cooley advised GeBBS Healthcare Solutions, a global provider of healthcare outsourcing solutions, and ChrysCapital, a top India-focused private equity firm, on the agreement for BPEA Private Equity Fund VIII (EQT Private Capital Asia) to acquire a controlling beneficial interest in GeBBS from ChrysCapital.

Cooley advised Luna Innovations, a global leader in advanced fiber optic-based technology, on its $50 million investment from White Hat Capital Partners and its acquisition of Silixa.

Cooley is advising Veritone, an artificial intelligence company, on its acquisition of Broadbean for $52 million.